View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsPhenomeX 향후 성장Future 기준 점검 2/6PhenomeX (는) 각각 연간 38.2% 및 23.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 53.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -21.6% 로 예상됩니다.핵심 정보38.2%이익 성장률53.74%EPS 성장률Life Sciences 이익 성장16.4%매출 성장률23.4%향후 자기자본이익률-21.55%애널리스트 커버리지Good마지막 업데이트05 Sep 2023최근 향후 성장 업데이트Consensus EPS estimates upgraded to US$1.13 loss Aug 24Consensus EPS estimates fall by 22% Aug 21Price target decreased by 29% to US$4.00 Aug 20Price target decreased by 31% to US$5.67 May 19Consensus revenue estimates decrease by 16%, EPS upgraded May 18PhenomeX Inc. Provides Earning Guidance for the Full Year of 2023May 12모든 업데이트 보기Recent updatesBruker Cellular Analysis, Inc. Files Form 15Oct 13Phenomex Announces Opto Memory B Discovery Human Workflow on the Beacon®? Optofluidic PlatformSep 28PhenomeX Inc. Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development WorkflowsSep 22Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark™ Platform to Revolutionize High Throughput Multiplexed Hands-Free ProteomicsSep 17Consensus EPS estimates upgraded to US$1.13 loss Aug 24Consensus EPS estimates fall by 22% Aug 21Price target decreased by 29% to US$4.00 Aug 20Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).Aug 19New major risk - Share price stability Aug 18New major risk - Financial position Aug 16Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 16PhenomeX Inc. to Report Q2, 2023 Results on Aug 14, 2023Aug 11PhenomeX Inc. Announces Lifting of the Stay in AbCellera Patent Infringement CaseAug 08PhenomeX Inc.(NasdaqGS:CELL) dropped from Russell Small Cap Comp Value IndexJun 25+ 2 more updatesPhenomeX Receives a Notice from Nasdaq Regarding Minimum Bid Price RuleJun 24PhenomeX Inc. Launches Beacon Quest™? Optofluidic System with Opto®? T Cell Profiling WorkflowsJun 06Price target decreased by 31% to US$5.67 May 19Consensus revenue estimates decrease by 16%, EPS upgraded May 18PhenomeX Inc. Launches Beacon Select Optofluidic System with Opto B Discovery WorkflowsMay 16Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)May 16First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 13PhenomeX Inc. Provides Earning Guidance for the Full Year of 2023May 12PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An OpportunityApr 17Full year 2022 earnings: EPS and revenues miss analyst expectations Feb 26Berkeley Lights, Inc. to Report Q4, 2022 Results on Feb 23, 2023Feb 14Berkeley Lights, Inc. Provides Preliminary Revenue Guidance for the Year Ended December 31, 2022Jan 10+ 1 more updateBerkeley Lights, Inc. (NasdaqGS:BLI) announced a definitive agreement to acquire IsoPlexis Corporation (NasdaqGS:ISO) from a group of shareholders for $56.3 million.Dec 23CEO & Director notifies of intention to sell stock Dec 16President of Global Operations notifies of intention to sell stock Nov 25Berkeley Lights Accelerating Antibody Discovery with Launch of Rabbit Memory B Cell WorkflowNov 19High number of new directors Nov 16Third quarter 2022 earnings: EPS misses analyst expectations Nov 09Berkeley Lights, Inc. Provides Revenue Guidance for the Year 2022Nov 09Berkeley Lights, Inc. to Report Q3, 2022 Results on Nov 08, 2022Oct 19Berkeley Lights, Inc. Announces Appointment of Scott Chaplin as Chief Legal Officer and Corporate SecretarySep 20CEO & Director notifies of intention to sell stock Sep 16President of Global Operations notifies of intention to sell stock Aug 26Consensus revenue estimates fall by 17% Aug 16Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue ForecastsAug 15Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 10Berkeley Lights, Inc. Provides Revenue Guidance for the Full Year 2022Aug 10Berkeley Lights, Inc. and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of A Patient-Derived T Cell Receptor Sequence Against A Cancer NeoantigenAug 05Berkeley Lights, Inc. Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate DevelopmentAug 02Berkeley Lights Inc. Announces Mehul Joshi as New Chief Financial OfficerJul 26Mehul Joshi joins Berkeley Lights as CFO Jul 25Berkeley Lights, Inc. to Report Q2, 2022 Results on Aug 09, 2022Jul 22Insider notifies of intention to sell stock May 15First quarter 2022 earnings: EPS misses analyst expectations May 10Price target decreased to US$16.80 Apr 27High number of new directors Apr 27Berkeley Lights, Inc., Annual General Meeting, May 26, 2022Apr 16Berkeley Lights Announces Appointment of Lucas S. Vitale as Chief Human Resources OfficerApr 14Insider recently bought US$502k worth of stock Mar 12Berkeley Lights, Inc. Releases Upgrade to Its Software Suite for Beacon and Lightning PlatformsMar 05Full year 2021 earnings: EPS and revenues exceed analyst expectations Feb 25Berkeley Lights, Inc. Reiterates Revenue Guidance for Full Year 2022Feb 25Price target decreased to US$30.40 Feb 24Berkeley Lights, Inc. to Report Q4, 2021 Results on Feb 24, 2022Feb 11Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead CaseFeb 06ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Berkeley Lights, IncJan 13High number of new directors Jan 08Berkeley Lights, Inc. Provides Revenue Guidance for Full Year of 2021 and 2022Jan 06Berkeley Lights, Inc. to Showcase its Optofluidic Discovery Technology At 2021 Antibody Engineering & Therapeutics ConferenceDec 10Berkeley Lights Grows Revenue But Operating Losses Mount Dec 09Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, IncDec 09Independent Chairman of the Board recently bought US$500k worth of stock Nov 12Are Investors Undervaluing Berkeley Lights, Inc. (NASDAQ:BLI) By 49%?Nov 07Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.16 loss in 3Q 2020) Nov 05Berkeley Lights: Short Seller Report Raises A Few Legitimate Questions Sep 23Chief Technology Officer notifies of intention to sell stock Sep 18Chief Technology Officer exercised options and sold US$132k worth of stock Sep 04Executive Officer Matthew Rosinack has left the company Sep 03Executive Officer notifies of intention to sell stock Aug 17Price target decreased to US$73.00 Aug 13Second quarter 2021 earnings released: US$0.27 loss per share (vs US$4.25 loss in 2Q 2020) Aug 13Berkeley Lights, Inc. Provides Revenue Guidance for the Year 2021Aug 12Chief Technology Officer exercised options and sold US$357k worth of stock Aug 08CEO & Director exercised options and sold US$697k worth of stock Jul 24Chief Technology Officer exercised options and sold US$362k worth of stock Jul 10Berkeley Lights, Inc.(NasdaqGS:BLI) dropped from Russell 2500 Value IndexJun 28+ 3 more updatesChief Technology Officer notifies of intention to sell stock Jun 11Independent Chairman of the Board recently bought US$206k worth of stock Jun 10Berkeley Lights Releases Subscription-Based Access Program and Signs First CustomersJun 02CEO & Director exercised options and sold US$620k worth of stock May 27Independent Chairman Michael Marks has left the company May 15First quarter 2021 earnings released: US$0.24 loss per share (vs US$3.03 loss in 1Q 2020) May 13Berkeley Lights, Inc. Provides Revenue Guidance for 2021May 12Chief Technology Officer exercised options and sold US$414k worth of stock May 01이익 및 매출 성장 예측NasdaqGS:CELL - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2025133-47-42-34512/31/2024102-64-51-45612/31/202376-106-60-5466/30/202372-125-68-66N/A3/31/202377-100-61-57N/A12/31/202279-98-56-48N/A9/30/202284-86-65-52N/A6/30/202287-85-68-50N/A3/31/202287-78-72-52N/A12/31/202185-72-69-53N/A9/30/202184-66-54-42N/A6/30/202178-54-45-39N/A3/31/202169-50-40-37N/A12/31/202064-43-39-36N/A9/30/202059-35-33-30N/A6/30/202057-32-31-26N/A3/31/202058-26-27-19N/A12/31/201957-21-19-11N/A12/31/201831-27-21-14N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CELL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: CELL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: CELL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: CELL 의 수익(연간 23.4%)이 US 시장(연간 11.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: CELL 의 수익(연간 23.4%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CELL는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/10/04 05:47종가2023/09/29 00:00수익2023/06/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PhenomeX Inc.는 8명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gaurav GoparajuBerenbergMark MassaroBTIGTycho PetersonJ.P. Morgan5명의 분석가 더 보기
PhenomeX Inc. Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development WorkflowsSep 22
Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark™ Platform to Revolutionize High Throughput Multiplexed Hands-Free ProteomicsSep 17
Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).Aug 19
PhenomeX Inc. Launches Beacon Quest™? Optofluidic System with Opto®? T Cell Profiling WorkflowsJun 06
Berkeley Lights, Inc. Provides Preliminary Revenue Guidance for the Year Ended December 31, 2022Jan 10+ 1 more update
Berkeley Lights, Inc. (NasdaqGS:BLI) announced a definitive agreement to acquire IsoPlexis Corporation (NasdaqGS:ISO) from a group of shareholders for $56.3 million.Dec 23
Berkeley Lights, Inc. Announces Appointment of Scott Chaplin as Chief Legal Officer and Corporate SecretarySep 20
Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue ForecastsAug 15
Berkeley Lights, Inc. and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of A Patient-Derived T Cell Receptor Sequence Against A Cancer NeoantigenAug 05
Berkeley Lights, Inc. Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate DevelopmentAug 02
Berkeley Lights, Inc. Releases Upgrade to Its Software Suite for Beacon and Lightning PlatformsMar 05
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead CaseFeb 06
ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Berkeley Lights, IncJan 13
Berkeley Lights, Inc. to Showcase its Optofluidic Discovery Technology At 2021 Antibody Engineering & Therapeutics ConferenceDec 10
